Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
ampicillin	O
/	O
Keflex	O
/	O
paclitaxel	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Scheduled	O
chemotherapy	O
for	O
Mullerian	O
carcinoma.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
None.	O
History	O
of	O
Present	O
Illness:	O
The	O
patient	O
is	O
a	O
___	O
year	O
old	O
female	O
with	O
stage	O
IV	O
high	O
grade	O
Mullerian	O
Carcinoma	O
here	O
for	O
chemotherapy	O
desensitization.	O
During	O
her	O
first	O
cycle	O
of	O
chemotherapy,	O
she	O
had	O
a	O
reaction	O
(SOB)	O
without	O
rash.	O
Since	O
then	O
she	O
has	O
tolerated	O
cycle	O
___	O
and	O
5	O
well	O
on	O
the	O
hypersensitivity	O
protocol.	O
Last	O
on	O
___.	O
Restaging	O
after	O
3	O
cycles	O
showed	O
improvement	O
in	O
R	O
inguinal	O
mass.	O
Today,	O
she	O
presents	O
for	O
cycle	O
6.	O
She	O
states	O
that	O
she	O
feels	O
well	O
and	O
denies	O
any	O
fevers,	O
chills,	O
chest	O
pain,	O
shortness	O
of	O
breath,	O
abdominal	O
pain	O
or	O
dysuria.	O
She	O
does	O
have	O
some	O
constipation.	B-Constipation
Past	O
Medical	O
History:	O
-	O
___	O
pt	O
noted	O
nontender	O
right	O
groin	O
mass	O
-	O
___	O
developed	O
right	O
leg	O
swelling	O
and	O
presented	O
to	O
her	O
PCP	O
___	O
___	O
-	O
___	O
presented	O
to	O
her	O
PCP;	O
evaluation	O
included	O
___	O
notable	O
for	O
5.4	O
cm	O
lesion	O
in	O
the	O
right	O
groin	O
with	O
flattened	O
waveforms	O
of	O
the	O
right	O
common	O
femoral	O
vein,	O
raising	O
concern	O
for	O
proximal	O
thrombus,	O
but	O
no	O
DVT	O
was	O
detected;	O
CT	O
AP	O
notable	O
for	O
a	O
4.6	O
x	O
3.3	O
x	O
3.9	O
cm	O
right	O
inguinal	O
soft	O
tissue	O
mass	O
likely	O
representing	O
a	O
conglomeration	O
of	O
lymphadenopathy	O
as	O
well	O
as	O
right	O
external	O
iliac	O
vein	O
with	O
central	O
filling	O
defect	O
concerning	O
for	O
DVT.	O
There	O
were	O
also	O
several	O
small	O
soft	O
tissue	O
density	O
nodules	O
seen	O
within	O
the	O
retroperitoneal	O
fat	O
and	O
no	O
mesenteric	O
lymphadenopathy.	O
Per	O
radiology	O
review,	O
the	O
pelvic	O
organs	O
were	O
unremarkable,	O
two	O
ill-defined	O
hypodense	O
lesion	O
as	O
well	O
as	O
6	O
mm	O
solid	O
right	O
lower	O
lobe	O
pulmonary	O
nodule.	O
-	O
___	O
US	O
guided	O
bx	O
groin	O
mass:	O
atypical	O
epithelial	O
cells,	O
concerning	O
for	O
malignancy	O
but	O
was	O
nondiagnostic	O
given	O
small	O
sample	O
size.	O
Started	O
on	O
Coumadin.	O
-	O
___	O
presented	O
to	O
ED	O
for	O
worsened	O
___	O
showed	O
deep	O
venous	O
thrombosis	O
in	O
the	O
right	O
common	O
femoral,	O
proximal	O
superficial	O
femoral	O
and	O
deep	O
femoral	O
veins.	O
CTA	O
chest	O
showed	O
two	O
segmental/subsegmental	O
LLL	O
pulmonary	O
emboli.	O
Again,	O
6	O
mm	O
solid	O
pulmonary	O
nodule	O
was	O
seen	O
in	O
the	O
RLL.	O
She	O
was	O
then	O
admitted	O
for	O
management	O
of	O
her	O
VTE	O
and	O
for	O
further	O
evaluation	O
of	O
her	O
groin	O
mass.	O
-	O
___	O
initial	O
CA	O
125	O
173	O
-	O
___	O
MRCP	O
showed	O
a	O
nonspecific	O
1.7	O
cm	O
hepatic	O
lesion	O
without	O
characteristics	O
consistent	O
with	O
metastasis	O
-	O
___	O
open	O
biopsy	O
of	O
the	O
right	O
groin	O
mass	O
showed	O
high-grade	O
serous	O
carcinoma	O
of	O
gynecologic	O
origin	O
-	O
___	O
discharged	O
on	O
therapeutic	O
lovenox	O
-	O
___	O
readmitted	O
due	O
to	O
cellulitis	O
at	O
site	O
of	O
excisional	O
biopsy	O
-	O
___	O
carboplatin/paclitaxel	O
C1D1	O
given	O
with	O
desensitization	O
due	O
to	O
allergy	O
to	O
paclitaxel	O
-	O
___	O
carboplatin/paclitaxel	O
C2D1	O
(11R)	O
-	O
___	O
carboplatin/paclitaxel	O
C3D1	O
(11R)	O
-	O
___	O
carboplatin/paclitaxel	O
C4D1	O
-	O
C5	O
carboplatin/paclitaxel	O
given	O
___	O
PAST	O
MEDICAL	O
HISTORY:	O
-	O
___	O
___	O
DVT,	O
enoxaparin	O
-	O
T2DM	O
-	O
HTN	O
-	O
COPD/emphysema	O
-	O
Anemia	O
-	O
Lipds	O
-	O
Hypothyroid	O
-	O
Seizure	B-Seizures
disorder,	O
tonic	B-Seizures
clonic,	B-Seizures
last	O
seizure	B-Seizures
___	O
-	O
One	O
atrophic	O
kidney	O
-	O
Vascular	O
claudication	O
-	O
Side	O
branch	O
IPMN	O
(incidentally	O
noted	O
on	O
imaging)	O
-	O
S/P	O
CCY	O
___	O
-	O
Childhood	O
kidney	O
biopsy	O
Social	O
History:	O
___	O
Family	O
History:	O
Denies	O
h/o	O
CAD,	O
CVA,	O
breast,	O
ovarian,	O
uterine,	O
cervical	O
or	O
colon	O
cancers.	O
T2DM,	O
HTN.	O
Sister	O
(___)	O
with	O
postpartum	O
DVT/PE.	O
Physical	O
Exam:	O
General:	O
NAD	O
VITAL	O
SIGNS:	O
T	O
97.7	O
BP	O
126/60	O
HR	O
78	O
RR	O
18	O
O2	O
97%	O
RA	O
HEENT:	O
MMM,	O
no	O
OP	O
lesions	O
PULM:	O
CTAB	O
ABD:	O
Soft,	O
NTND,	O
no	O
masses	O
or	O
hepatosplenomegaly	O
LIMBS:	O
No	O
edema,	O
clubbing,	O
tremors,	O
or	O
asterixis	O
SKIN:	O
No	O
rashes	O
or	O
skin	O
breakdown	O
NEURO:	O
Alert	O
and	O
oriented.	B-Delirium
No	O
focal	O
deficits.	O
Pertinent	O
Results:	O
___	O
06:08AM	O
BLOOD	O
WBC-6.4	O
RBC-2.74*	O
Hgb-9.7*	O
Hct-28.3*	O
MCV-103*	O
MCH-35.4*	O
MCHC-34.3	O
RDW-17.8*	O
RDWSD-68.1*	O
Plt	O
Ct-87*	O
___	O
06:08AM	O
BLOOD	O
Glucose-196*	O
UreaN-17	O
Creat-0.7	O
Na-138	O
K-4.2	O
Cl-103	O
HCO3-25	O
AnGap-14	O
___	O
06:08AM	O
BLOOD	O
ALT-50*	O
AST-48*	O
TotBili-0.3	O
___	O
06:08AM	O
BLOOD	O
Calcium-7.8*	O
Phos-3.0	O
Mg-1.___	O
year	O
old	O
female	O
with	O
stage	O
IV	O
high	O
grade	O
Mullerian	O
Carcinoma	O
here	O
for	O
paclitaxel	O
chemotherapy	O
desensitization.	O
Stage	O
IV	O
Mullerian	O
carcinoma	O
-	O
Recieved	O
cycle	O
6	O
carboplatin/paclitaxel	O
with	O
hypersensitivity	O
protocol	O
and	O
tolerated	O
well	O
without	O
issue.	O
Will	O
follow	O
up	O
with	O
her	O
primary	O
oncologist	O
as	O
an	O
outpatient.	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Apixaban	O
5	O
mg	O
PO	O
BID	O
2.	O
LeVETiracetam	O
500	O
mg	O
PO	O
BID	O
3.	O
Levothyroxine	O
Sodium	O
125	O
mcg	O
PO	O
DAILY	O
4.	O
Simvastatin	O
10	O
mg	O
PO	O
QPM	O
5.	O
Ascorbic	O
Acid	O
___	O
mg	O
PO	O
BID	O
6.	O
Ferrous	O
Sulfate	O
325	O
mg	O
PO	O
DAILY	O
7.	O
Losartan	O
Potassium	O
50	O
mg	O
PO	O
DAILY	O
8.	O
MetFORMIN	O
XR	O
(Glucophage	O
XR)	O
1000	O
mg	O
PO	O
BID	O
9.	O
Glargine	O
20	O
Units	O
Bedtime	O
Discharge	O
Medications:	O
1.	O
Glargine	O
20	O
Units	O
Bedtime	O
2.	O
LeVETiracetam	O
500	O
mg	O
PO	O
BID	O
3.	O
Levothyroxine	O
Sodium	O
125	O
mcg	O
PO	O
DAILY	O
4.	O
Ferrous	O
Sulfate	O
325	O
mg	O
PO	O
DAILY	O
5.	O
Ascorbic	O
Acid	O
___	O
mg	O
PO	O
BID	O
6.	O
Apixaban	O
5	O
mg	O
PO	O
BID	O
7.	O
Simvastatin	O
10	O
mg	O
PO	O
QPM	O
8.	O
MetFORMIN	O
XR	O
(Glucophage	O
XR)	O
1000	O
mg	O
PO	O
BID	O
9.	O
Losartan	O
Potassium	O
50	O
mg	O
PO	O
DAILY	O
10.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID:PRN	O
Constipation	B-Constipation
RX	O
*docusate	O
sodium	O
100	O
mg	O
1	O
capsule(s)	O
by	O
mouth	O
Twice	O
a	O
day	O
Disp	O
#*60	O
Capsule	O
Refills:*0	O
11.	O
Ondansetron	O
8	O
mg	O
PO	O
DAILY	O
Duration:	O
2	O
Days	O
RX	O
*ondansetron	O
8	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
Daily	O
Disp	O
#*1	O
Tablet	O
Refills:*0	O
Discharge	O
Disposition:	O
Home	O
Discharge	O
Diagnosis:	O
Mullerian	O
Carcinoma	O
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
for	O
scheduled	O
chemotherapy	O
with	O
carboplatin	O
and	O
paclitaxel.	O
You	O
tolerated	O
the	O
chemotherapy	O
well.	O
Followup	O
Instructions:	O
___	O

